Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3361-3363

  Cressey, Tim R ^a,b   Nangola, Sawitree ^b   Tawon, Yardpiroon ^b   Pattarawarapan, Mookda ^b   Lallemant, Marc ^a,b   Tayapiwatana, Chatchai ^b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c Faculty of Associated Medical Sciences   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ARTICLE; CHROMATOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; EARLY DIAGNOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCHROMATOGRAPHIC STRIP TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; ANTI-HIV AGENTS; CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCHEMISTRY; NEVIRAPINE;

EID: 35948980732     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00445-07     Document Type: Article

References (12)

1. Autar, R. S., F. W. Wit, J. Sankote, A. Mahanontharit, T. Anekthananon, P. Mootsikapun, K. Sujaikaew, D. A. Cooper, J. M. Lange, P. Phanuphak, K. Ruxrungtham, and D. M. Burger. 2005. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir. Ther. 10:937-943.
2. Chi, B. H., A. Lee, E. P. Acosta, L. E. Westerman, M. Sinkala, and J. S. Stringer. 2006. Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood. HIV Clin. Trials 7:263-269.
3. Crommentuyn, K. M., A. D. Huitema, K. Brinkman, M. E. van der Ende, F. de Wolf, and J. H. Beijnen. 2005. Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study. J. Acquir. Immune Defic. Syndr. 39:249-250.
4. Droste, J. A., C. P. Verweij-Van Wissen, and D. M. Burger. 2003. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther. Drug Monit. 25:393-399.
5. Dubuisson, J. G., J. R. King, J. S. Stringer, M. L. Turner, C. Bennetto, and E. P. Acosta. 2004. Detection of nevirapine in plasma using thin-layer chromatography. J. Acquir. Immune Defic. Syndr. 35:155-157.
6. Hugen, P. W., D. M. Burger, R. E. Aarnoutse, P. A. Baede, P. T. Nieuwkerk, P. P. Koopmans, and Y. A. Hekster. 2002. Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance. Ther. Drug Monit. 24:579-587.
7. Khoo, S. H., J. Lloyd, M. Dalton, A. Bonington, E. Hart, S. Gibbons, P. Flegg, J. Sweeney, E. G. Wilkins, and D. J. Back. 2006. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN): a randomized controlled trial of therapeutic drug monitoring and adherence support. J. Acquir. Immune Defic. Syndr. 41:461-467.
8. Lallemant, M., G. Jourdain, S. Le Coeur, J. Y. Mary, N. Ngo-Giang-Huong, S. Koetsawang, S. Kanshana, K. Mcintosh, and V. Thaineua. 2004. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 351:217-228.
9. Pattarawarapan, M., S. Nangola, T. R. Cressey, and C. Tayapiwatana. 2007. Development of a one-step immunochromatographic strip test for the rapid detection of nevirapine (NVP), a commonly used antiretroviral drug for the treatment of HIV/AIDS. Talanta 71:462-470.
10. U.S. Department of Health and Human Services. 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD.
11. Veldkamp, A. I., R. P. van Heeswijk, J. W. Mulder, P. L. Meenhorst, G. Schreij, S. van der Geest, J. M. Lange, J. H. Beijnen, and R. M. Hoetelmans. 2001. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 27:344-349.
12. World Health Organization. 2006. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach. World Health Organization, Geneva, Switzerland.